LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.
A legfontosabb adatok
- Ki végzi
- M. Medici
- Hol
- Almere Stad, Amsterdam, Apeldoorn, Arnhem, Breda, Dirksland, Dordrecht, Emmen, Goes, Groningen, Hardenberg, Nijmegen, Rotterdam, Schiedam, Sittard, Utrecht, Veldhoven és Venlo (Hollandia)Mind a 19 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 600 fő, tervezett
- Kezdés
- 2022. okt. 7.
- Várható befejezés
- 2028. jan.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- LT3 (liothyronine)
- Placebo
- A regiszteradat frissítve
- 2025. február 26.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with autoimmune hypothyroidism (underactive thyroid) who still feel severely tired while taking LT4 alone.
- Életkor
- 18 years or older
- Nem
- All sexes
- A betegség stádiuma
- Overt or subclinical primary hypothyroidism caused by autoimmunity. Severe tiredness with a large impact on daily life for at least 6 months.
- Korábbi kezelés
- LT4 alone for at least 6 months, at a dose of 75-225 microg and at least 1.2 microg/kg. No thyroid surgery, radioactive iodine, or head and/or neck radiotherapy.
- Biomarker vagy leletérték
- TSH levels within the normal reference range for at least 3 months. Thyroid antibody (TPO or Tg) results are not required.
A részvétel fő kizáró okai
- Other causes of hypothyroidism, such as congenital, after thyroiditis, or central hypothyroidism
- Use of drugs that affect the thyroid, such as amiodarone, lithium, interferon or immunotherapy
- Heart problems, including atrial fibrillation, recent heart attack or unstable angina, or ECG conduction problems
- Pregnancy, breastfeeding, wish to become pregnant within 2 years, or no reliable contraception
- Another clear reason for tiredness, dementia, or psychiatric disease treated in specialised mental health care
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Patients with overt or subclinical primary hypothyroidism 18 years or older.*
- LT4 monotherapy for at least 6 months
- LT4 monotherapy dose of 75-225 microg, with at least a dose of 1.2 microg/kg
- TSH levels within the assay-specific reference ranges for at least 3 months
- Severe tiredness with a large negative impact on daily life for at least 6 months, with or without other persisting complaints. This is based on the patient's own experience, without judgment of the treating physician
- Sufficiently fluent in Dutch and able to read Dutch; Thyroid peroxidase (TPO) and/or thyroglobulin (Tg) antibody positivity is not a requirement as these have frequently not been determined. Instead, we ensure that we only include patients with autoimmune hypothyroidism by excluding other causes of hypothyroidism (see exclusion criteria)
Ki nem vehet részt
- Thyroid surgery, radioactive iodine treatment, or head and/or neck radiotherapy
- Use of thyroid interfering drugs (current/past use of amiodarone, immunotherapy, tyrosin kinase inhibitors, interferon, or lithium and current use of oral or iv corticosteroids or dopamine)
- Current psychiatric disease treated at a "gespecialiseerde GGZ instelling"**
- Clinical diagnosis of dementia
- Clinically relevant functional or structural abnormal heart (e.g., cardiomyopathy or valve disease)
- Recent acute coronary syndrome or unstable angina pectoris (<4 weeks)
- Other obvious medical explanation for tiredness (e.g. end-stage renal disease, anemia, COPD stage IV, cancer, etc.)
- Other obvious major life event explanation for tiredness (e.g., mourning, loss of job); Postpartum thyroiditis is not an exclusion criterium; Treatments of mild non-complex psychological/psychiatric complaints are done in the " basis GGZ", e.g. consisting of conversations with a psychologist or psychotherapist, or via internet (e-health). "Gespecialiseerde GGZ" encompasses treatments of more severe psychological/psychiatric complaints. (link: Basis GGZ en gespecialiseerde GGZ | Geestelijke gezondheidszorg (GGZ) | Rijksoverheid.nl)
- Current conduction disorder on ECG (i.e, QRS>120 ms or prolonged QTc (women≥460 ms and men≥450 ms))
- Women of reproductive age not using adequate contraception, who are not sterilized and do not have a sterilized partner. Adequate contraceptives include the contraceptive pill, patch, injection, implant, intrauterine device or system, vaginal ring, diaphragm or cap, and condom
- Congenital hypothyroidism, hypothyroidism after (sub)acute thyroiditis*, secondary (central) hypothyroidism
- Pregnancy, breastfeeding or wish to become pregnant within 2 years
- Current/past atrial fibrillation
- Frequent ventricular extrasystole (=doublet, trigeminy, bigeminy or (non-sustained) ventricular tachycardia) in the past or on current ECG
Ez a vizsgálat jelenleg itt érhető el: Hollandia.
- FlevoziekenhuisAlmere Stad, HollandiaContact: Antoon Van Lierop, MD PhDRésztvevőt keres
- Amsterdam UMC, location AMCAmsterdam, HollandiaContact: Eveline Bruinstroop, MD PhDRésztvevőt keres
- Gelre ZiekenhuizenApeldoorn, HollandiaContact: Marlies Bosselaar, MD PhDToborzás még nem indult
- RijnstateArnhem, HollandiaContact: Sean Roerink, MD PhDRésztvevőt keres
- Amphia ZiekenhuisBreda, HollandiaContact: Charlotte Krol, MD PhDRésztvevőt keres
- Van Weel-Bethesda HospitalDirksland, HollandiaContact: Ellen v Schaik, MDRésztvevőt keres
- Albert Schweitzer HospitalDordrecht, HollandiaContact: Rosalie Kiewiet-Kemper, MD PhDRésztvevőt keres
- TreantEmmen, HollandiaContact: Eveline van Dam, MD PhDToborzás még nem indult
- Admiraal de Ruyter HospitalGoes, HollandiaContact: Kees vd Berge, MD PhDRésztvevőt keres
- University Medical Center GroningenGroningen, HollandiaContact: Wouter Zandee, MD PhDRésztvevőt keres
- Saxenburgh MCHardenberg, HollandiaContact: Simone Spoorenberg, MD PhDRésztvevőt keres
- RadboudumcNijmegen, HollandiaContact: Romana Netea-Maier, Prof. dr.Résztvevőt keres
- Erasmus Medical CenterRotterdam, HollandiaContact: Marco Medici, MD PhDRésztvevőt keres
- Maasstad HospitalRotterdam, HollandiaContact: Charlotte v Noord, MD PhDRésztvevőt keres
- Franciscus Gasthuis & VlietlandSchiedam, HollandiaContact: Marlies Kevenaar, MD PhDRésztvevőt keres
- ZuyderlandSittard, HollandiaContact: Roderick Tummers-de Lind van Wijngaarden, MD PhDRésztvevőt keres
- University Medical Center UtrechtUtrecht, HollandiaContact: Stephanie vd Leij, MDRésztvevőt keres
- Maxima Medical CenterVeldhoven, HollandiaContact: Pleun Wouters-van Poppel, MD PhDRésztvevőt keres
- Vie Curie MCVenlo, HollandiaContact: Joop van den Bergh, Prof. dr.Toborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Hypothyroidism is common, affecting 5% of the general population, for which levothyroxine (LT4) monotherapy is the standard treatment. Despite normalized serum thyroid hormone levels, 10-15% of LT4 treated patients have various persistent complaints, the most important of which is tiredness. This could be explained by the fact that physiological T4/T3 ratios cannot be reached with LT4 monotherapy, as in a healthy individual T3 is not only derived from T4/T3 conversion but is also directly produced by the thyroid itself. Studies have reported contradicting results as to whether addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy is effective or not. Studies have suggested higher effectiveness in patients carrying genetic variation in the type 2 deiodinase (DIO2-rs225014) and monocarboxylate transporter 10 (MCT10-rs17606253) genes.
A teljes eredeti leírásKevesebb
Objective: To investigate whether addition of liothyronine (LT4/LT3 combination therapy) in in patients with persistent tiredness on LT4 monotherapy is effective or not in relieving tiredness.
A vizsgálat 2 csoportja
- LT4/LT3 combination therapyMár használt kezelés, összehasonlításként
The intervention group is treated with once daily a LT4 tablet and twice daily a LT3 tablet with a LT4:LT3 ratio 16:1.
Kezelés: LT3 (liothyronine)
- LT4/placebo therapyPlacebo, összehasonlításként
The control group is treated with once daily a LT4 tablet and twice daily a placebo tablet.
Kezelés: Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A National Randomized Placebo-controlled Double-blind Multicenter Trial of LT4/LT3 Combination Therapy in Patients with Autoimmune Hypothyroidism: the T3-4-Hypo Trial.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Publikációk
- A feasibility double-blind trial of levothyroxine vs. levothyroxine-liothyronine in postsurgical hypothyroidism.Frontiers in endocrinology, 2025
- A regiszteradat frissítve
- 2025. február 26.